Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
This Community Practice Connections™ program provides an in-depth review of foundational data supporting the optimal management of hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancers (MBC) harboring ESR1 mutations. This unique, engaging, multimedia activity is ideal for the community-based clinician; it focuses on the practical aspects of treating patients with ESR1-mutated MBC, putting recent practice guidelines and trial data into clinical context with commentary by experts in the field. Participants will examine best practices for testing and identifying ESR1 mutations and discuss data supporting the use of oral selective estrogen receptor downregulators for treating these cancers. The program will also address the management of patients with concurrent PIK3CA/AKT/PTEN alterations and novel combination regimens being explored, providing practical insights to improve patient care.
Target Audience
This educational program is primarily directed toward community-based medical oncologists, surgical oncologists, advanced practice providers, nurses, and other health care providers involved in the treatment of MBC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply guideline-concordant approaches for molecular testing in patients with HR+/HER2– MBC across the disease continuum
- Evaluate recent real-world evidence providing practical insights into the use of targeted treatment strategies for HR+/HER2–MBC
- Integrate clinical trial and real-world data alongside patient- and disease-specific characteristics into personalized treatment decisions for patients with HR+/HER2– MBC
- Develop evidence-based strategies for monitoring and mitigating adverse effects associated with targeted therapies for HR+/HER2- MBC
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here